Regier, D.A.; Chan, B.; Costa, S.; Scott, D.W.; Steidl, C.; Connors, J.M.; Karsan, A.; Marra, M.A.; Kridel, R.; Cromwell, I.;
et al. Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60. Cancers 2022, 14, 908.
https://doi.org/10.3390/cancers14040908
AMA Style
Regier DA, Chan B, Costa S, Scott DW, Steidl C, Connors JM, Karsan A, Marra MA, Kridel R, Cromwell I,
et al. Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60. Cancers. 2022; 14(4):908.
https://doi.org/10.3390/cancers14040908
Chicago/Turabian Style
Regier, Dean A., Brandon Chan, Sarah Costa, David W. Scott, Christian Steidl, Joseph M. Connors, Aly Karsan, Marco A. Marra, Robert Kridel, Ian Cromwell,
and et al. 2022. "Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60" Cancers 14, no. 4: 908.
https://doi.org/10.3390/cancers14040908
APA Style
Regier, D. A., Chan, B., Costa, S., Scott, D. W., Steidl, C., Connors, J. M., Karsan, A., Marra, M. A., Kridel, R., Cromwell, I., & Pollard, S.
(2022). Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60. Cancers, 14(4), 908.
https://doi.org/10.3390/cancers14040908